T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease. Issue 1 (14th March 2022)

• Record Type: Journal Article
• Authors: Shadyab, Aladdin H.; LaCroix, Andrea Z.; Matthews, Genevieve; Bennett, Daniel; Shadyab, Alexandre A.; Tan, Donna; Thomas, Ronald G.; Mason, Jennifer; Lopez, Alex; Askew, Brianna; Donahue, Lia; Kaplita, Stephen; Qureshi, Irfan A.; Huisa, Branko; Feldman, Howard H.
• Is Part Of: Alzheimer's & dementia. Volume 8:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-14
• Subjects: Alzheimer's disease -- clinical trial -- drug development -- pharmacologic -- recruitment; Dementia -- Periodicals; Dementia -- Treatment -- Periodicals; Alzheimer's disease -- Treatment -- Periodicals; Alzheimer's disease -- Periodicals; 616.831
• DOI: 10.1002/trc2.12265
• Languages: English
• ISSNs: 2352-8737

Abstract

Abstract: Introduction: The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress. Methods: T2 Protect AD (T2), a phase 2 randomized placebo‐controlled trial of troriluzole in mild to moderate AD, used multiple recruitment strategies. Results: T2 exceeded its recruitment target, enrolling 350 participants between July 2018 and December 2019 (randomization rate: 0.87 randomizations/site/month, or 3‐fold greater than recent trials of mild to moderate AD). The vast majority (98%) of participants were enrolled during a 10‐month window of intense promotion in news media, TV and radio advertisements, and social media. The distribution of primary recruitment sources included: existing patient lists at participating sites (72.3%), news media (12.3%), physician referral (6.0%), word of mouth (3.1%), and paid advertising (2.9%). Discussion: The rapid recruitment of participants with mild to moderate AD was achieved through a range of approaches with varying success.